-
Miranda Lambert Leads North Texans with Seven Grammy Nominations for 2027
-
DiDi Advances Robotaxi Operations in China with New R2 Vehicle and Expanded Safety Infrastructure
-
Smart Car Seats Tested: Do Sensors and Apps Actually Improve Safety?
-
XPENG Launches Two New Models in UK; Pony.ai Robotaxi Enters Pilot
-
NexCore and MetLife Investment Management Launch $1.3 Billion Senior Living Co-Investment Venture
-
Galway Metals Intersects 1.8 g/t Gold Over 25.0 Metres and 0.7 g/t Gold Over 66.0 Metres at Clarence Stream
-
RuffleButts + RuggedButts Featured in Hasbro's 2026 Holiday Gift Guide
-
KIDZ AI Announces Strategic Collaboration with Synestria to Optimize AI Infrastructure Performance
-
Brightline Interactive and TruWeather Solutions Sign MOU to Bring Weather Data into SpatialCore Physical AI Platform
-
Avino Announces Key Technical Appointment
-
HippoFi Achieves OTCID Market Designation, Opening a New Chapter of Commercial Growth
-
Gabriel Resources Provides Corporate and Financing Update
-
MedMira Receives U.S. FDA Breakthrough Device Designation for Its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
-
Pivotree Announces Third Quarter 2026 Results
-
Ur-Energy Commences Baseline Study Fieldwork; Nears Completion of Technical Report at Lost Soldier Uranium Project, Wyoming
-
ImageWorks Display Advances Whole-Store Solutions with a Re-Imagined Planniq Strong and Planniq Chill
-
Razavi Law Group Partners with Chapman University to Prepare the Next Generation of Attorneys
-
Broad Clinical Labs Drives Strong Digital Engagement by Connecting Customers with Published Research Through Bioz
-
PRAAMS AI Co-Investor Now Covers 400,000+ Global Instruments, With Responses From 3 Seconds, Cost From US$0.01, and Scalability to Millions of Users
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 17
-
Driving Global Innovation - GTDC Summit APJ Underscores Distribution's Transformative Power
-
Pilot-Founded Solara Global Jet Offers Charter, Leases and Air Cargo Nationwide and Overseas
-
How to Turn Your Garage into Usable Living Space
-
Glidewell Opens Applications for 2027 Guiding Leaders Cohorts in California and North Carolina
-
The Next Healthcare Story Worth Telling May Be About Someone You Know
-
NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox (Monkeypox)
-
Atlas Signal Initiates Coverage of High Roller Technologies: ROLR(TM) Prediction-Markets Platform Goes Live on iPhone for U.S. Customers
-
Join Nord Precious Metals' Live Investor Webinar: Advancing Silver Production and High-Grade Exploration in Ontario
-
Executing Our Plan, Increasing Equity and Reducing Liabilities in Order to Build Long-Term Value
-
Dermata Highlights Additional Results and Photos from Cosmetic Study Evaluating Its Tome Foundational Treatment
-
Nexscient Reports Third Quarter 2026 Results; Revenue Rises Sequentially as Gross Margin Expands to Over 40%
-
Viking Global Technologies Announces Expansion of Grid Protection Technology Pilot with Another Major U.S. Electric Utility
-
TRNR Reports Record Q3 2026 Results, Driven by 66% Revenue Growth; M&A Pipeline Grows Significantly
-
Pinnacle Food Group Limited Achieves Laboratory-Scale Astaxanthin Extraction in Haematococcus pluvialis Program
-
FaZe Esports, a GameSquare Company, Wins Rainbow Six Championship at Osaka Major
-
Waste Energy to Host Shareholder Update Today at 4:30 PM EST; Management to Discuss WE #1 Commissioning, Revenue Opportunities and Growth Strategy
-
Klique Joins Lenovo AI Innovators, Bringing Its Enterprise AI Control Plane to Lenovo Hybrid AI Factory
-
Miami Allstars FC have Applied to Compete in the Women's Premier Soccer League, with the Club Targeting a 2027 or 2028 Debut in North Miami, Florida
-
Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
-
International Business Times UK Increases Programmatic Revenue by 30% with Opti Digital
-
Tectonic Metals Completes Record Drill Program at Flat, Advances Five Pillars of Growth Toward Major 2027 Milestones
-
BioLargo Reports Third Quarter 2026 Results, Forecasting Commercial Breakout in 2027
-
Three Inaugural CombatX Champions Crowned at BRAVE CF Road to BRAVE Event in Hungary
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
-
US Retail Sales and Fed Minutes Set Up a Critical Test for Consumers
-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Luxury Skincare Brand Faces Backlash Over Futurist Manifesto Aesthetic
Will DEA Cole Dismantle Marijuana Research Blockade - MMJ Biopharma Will Be His First Test Case
WASHINGTON, DC / ACCESS Newswire / August 5, 2025 / When President Donald Trump nominated Terrance C. "Terry" Cole to lead the U.S. Drug Enforcement Administration (DEA), it was a clear signal: Cole's primary mission was to dismantle cartels, combat the synthetic opioid crisis, and restore enforcement-first leadership at an agency long mired in political controversy. With a 22-year career at DEA, followed by a successful stint as Virginia's Secretary of Public Safety, Cole embodies the hardened operational mindset of an agency laser-focused on disruption of illicit drug networks.
But now, as DEA Administrator, Cole faces a leadership test that law enforcement experience alone cannot solve: Will he continue the agency's institutional stonewalling of legitimate cannabis pharmaceutical research, or will he embrace scientific integrity and public health necessity by facilitating companies like MMJ BioPharma Cultivation in their quest to bring FDA-approved cannabinoid medicines to patients suffering from Huntington's Disease and Multiple Sclerosis?

Cole's Resume: Enforcement Rigor, but Regulatory Inertia?
Terry Cole's career achievements are unquestionable. He oversaw complex anti-cartel operations in Mexico and Central America, served as DEA's liaison to the National Security Council, and, as Virginia's chief public safety official, led the state to a 44% reduction in overdose deaths in under a year. These are hard data points that speak to Cole's operational success in traditional enforcement.
However, the regulatory side of DEA-particularly its Diversion Control Division-remains deeply flawed. The same bureaucratic apparatus that protected the University of Mississippi's research cannabis monopoly for 50 years has now turned to sabotaging private pharmaceutical developers through endless procedural delays. Cole's predecessors enabled this rot. The question is whether his enforcement first philosophy blinds him to the agency's scientific accountability failures.
Boise's Resume: A Public Health Mission Obstructed by DEA Old Guard
On the other side stands Duane Boise, President & CEO of MMJ International Holdings. A humanitarian entrepreneur with a 30 year track record in healthcare innovation, Boise has achieved milestones that any biotech CEO would envy: FDA Orphan Drug Designation, two active Investigational New Drug (IND) applications, and a DEA-approved Schedule I analytical lab registration.
But despite MMJ's regulatory compliance, the DEA has refused to grant a Bulk Manufacturing Registration, effectively halting clinical trials for plant-derived cannabinoid therapies targeting neurological diseases. For over seven years, MMJ's applications have been entangled in a system designed to protect status quo interests, not scientific progress.
Cole's Enforcement Mindset Needs a Public Health Reality Check
Terry Cole's nomination under Trump was built on a mandate of enforcement and operational disruption. This makes him instinctively cautious-if not resistant-toward cannabis rescheduling debates and broader reform agendas. However, the MMJ BioPharma case is not about recreational legalization or policy rhetoric. It's about pharmaceutical-grade, FDA-regulated medicines for debilitating diseases.
Cole's enforcement instincts must now evolve to recognize a critical distinction:
Illicit drug cartels trafficking fentanyl are the enemy of public safety.
Federally compliant pharmaceutical developers like MMJ BioPharma are allies of public health.
The same laser-focused leadership that Cole used to dismantle cartel networks must now be directed inward-toward rooting out the institutional sabotage within the DEA's own licensing apparatus.
What Cole Must Do-Now
For Cole to succeed as a transformative leader rather than a caretaker of bureaucratic inertia, he must:
Approve MMJ BioPharma's Bulk Manufacturing Registration immediately.
Disband the DEA's internal regulatory traps that have strangled cannabis pharmaceutical research under the guise of "diversion control."
Align DEA policy with the Medical Marijuana and Cannabidiol Research Expansion Act (MCREA), ensuring that qualified applicants receive a fair and timely path to approval.
Hold accountable those within the DEA's licensing division who have weaponized procedural tactics to obstruct science.
The Legacy Crossroads
Terry Cole's enforcement résumé has earned him the credibility to confront America's most dangerous narcotics traffickers. But his legacy will not be defined by how many cartel leaders he pursues; it will be judged by whether he had the vision to modernize the DEA into an agency that can differentiate between criminal enterprises and scientific innovation.
If Cole ignores the compelling evidence presented by MMJ BioPharma-FDA designations, DEA lab registrations, and clinical urgency-he will perpetuate the very regulatory stagnation that has rendered the DEA's cannabis policy a global embarrassment.
But if he acts decisively, Terry Cole has the chance to pivot from enforcement hawk to reformer-a leader who finally corrected the agency's war on science.
The choice is his.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
W.Morales--AT